These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 23434734)

  • 41. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
    Witzig TE; Reeder C; Han JJ; LaPlant B; Stenson M; Tun HW; Macon W; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic S; Nowakowski GS; Gupta M
    Blood; 2015 Jul; 126(3):328-35. PubMed ID: 25921059
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J; Chen Y; Wan J; Liu X; Yu C; Li W
    Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
    Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
    Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
    Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapamycin inhibits tumor growth of human osteosarcomas.
    Zhao S; Lu N; Chai Y; Yu X
    J BUON; 2015; 20(2):588-94. PubMed ID: 26011354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
    Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
    Chang Q; Chen E; Hedley DW
    Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
    Yang Q; Zhang S; Kang M; Dong R; Zhao J
    Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
    Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
    Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N; Kanki K; Shimizu H; Shiota G
    Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
    Jiang H; Zeng Z
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.